Idera Pharmaceuticals Company Profile (NASDAQ:IDRA)

About Idera Pharmaceuticals

Idera Pharmaceuticals logoIdera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The Company utilizes two drug discovery technology platforms to design and develop drug candidates, which include Toll-like receptor (TLR) targeting technology and third-generation antisense (3GA) technology. Using TLR technology, the Company designs synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. Using its 3GA technology, the Company is developing drug candidates to turn off the messenger ribo nucleic acid (mRNA) associated with disease causing genes. The Company's drug candidates include IMO-8400; IMO-2125/IMO-2055, and IMO-9200. The Company's TLR antagonist lead drug candidates are IMO-8400 and IMO-9200, which are both antagonists of TLR7, TLR8 and TLR9. Its TLR agonist lead drug candidates are IMO-2055 and IMO-2125, which are both agonists of TLR9.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: IDRA
  • CUSIP:
Key Metrics:
  • Previous Close: $1.74
  • 50 Day Moving Average: $1.52
  • 200 Day Moving Average: $1.81
  • 52-Week Range: $1.19 - $3.33
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.14
  • P/E Growth: 0.00
  • Market Cap: $256.92M
  • Outstanding Shares: 147,653,000
  • Beta: 2.53
Profitability:
  • Net Margins: -4,621.03%
  • Return on Equity: -76.66%
  • Return on Assets: -68.43%
Debt:
  • Debt-to-Equity Ratio: 0.01%
  • Current Ratio: 7.07%
  • Quick Ratio: 7.06%
Additional Links:
Companies Related to Idera Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Idera Pharmaceuticals (NASDAQ:IDRA) (?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $4.05 (132.76% upside)

Analysts' Ratings History for Idera Pharmaceuticals (NASDAQ:IDRA)
Show:
DateFirmActionRatingPrice TargetDetails
1/31/2017WedbushReiterated RatingOutperform$6.00View Rating Details
11/29/2016Cowen and CompanyReiterated RatingOutperformView Rating Details
10/7/2016S&P Equity ResearchBoost Price Target$1.86 -> $2.10View Rating Details
3/12/2016Piper Jaffray CompaniesReiterated RatingBuyView Rating Details
6/15/2015J P Morgan Chase & CoInitiated CoverageOverweight$6.00View Rating Details
(Data available from 2/19/2015 forward)

Earnings

Earnings History for Idera Pharmaceuticals (NASDAQ:IDRA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/8/2017        
10/28/2016Q3($0.11)($0.10)ViewN/AView Earnings Details
5/9/2016Q1($0.11)($0.11)ViewListenView Earnings Details
3/10/2016Q4($0.11)($0.10)$20.00 millionViewN/AView Earnings Details
11/6/2015Q315($0.11)($0.10)ViewN/AView Earnings Details
8/6/2015Q215($0.11)($0.11)ViewN/AView Earnings Details
5/11/2015Q1($0.11)($0.12)$0.03 millionViewN/AView Earnings Details
3/12/2015Q414($0.11)($0.14)$0.03 millionViewN/AView Earnings Details
11/7/2014Q314($0.11)($0.11)ViewListenView Earnings Details
8/12/2014Q214($0.09)($0.10)ViewListenView Earnings Details
5/13/2014Q114($0.08)($0.12)ViewListenView Earnings Details
3/13/2014Q4($0.08)($0.10)ViewListenView Earnings Details
11/14/2013Q3($0.11)($0.11)$0.03 million$0.01 millionViewListenView Earnings Details
8/15/2013Q213($0.12)($0.15)ViewN/AView Earnings Details
5/15/2013Q113($0.19)($0.15)ViewN/AView Earnings Details
3/11/2013Q4 2012($0.24)ViewN/AView Earnings Details
11/12/2012Q312($0.17)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Idera Pharmaceuticals (NASDAQ:IDRA)
Current Year EPS Consensus Estimate: $-0.42 EPS
Next Year EPS Consensus Estimate: $-0.42 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.11)($0.10)($0.11)
Q2 20161($0.11)($0.11)($0.11)
Q3 20162($0.11)($0.09)($0.10)
Q4 20161($0.01)($0.01)($0.01)
Q1 20171($0.09)($0.09)($0.09)
Q2 20171($0.10)($0.10)($0.10)
Q3 20171($0.10)($0.10)($0.10)
Q4 20171($0.10)($0.10)($0.10)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Idera Pharmaceuticals (NASDAQ:IDRA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Idera Pharmaceuticals (NASDAQ:IDRA)
Insider Ownership Percentage: 29.50%
Institutional Ownership Percentage: 23.23%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/7/2016Julian BakerDirectorBuy3,250,000$2.00$6,500,000.00View SEC Filing  
10/3/2016Maxine GowenDirectorBuy4,102$2.56$10,501.12View SEC Filing  
5/13/2016James A GeraghtyDirectorBuy10,000$1.34$13,400.00View SEC Filing  
5/12/2016Mark J CaseyVPBuy34,450$1.44$49,608.00View SEC Filing  
3/15/2016Vincent MilanoCEOBuy40,000$1.97$78,800.00View SEC Filing  
2/13/2015Julian BakerDirectorBuy5,333,333$3.75$19,999,998.75View SEC Filing  
12/16/2014Youssef El ZeinDirectorSell100,000$3.68$368,000.00View SEC Filing  
12/12/2014Vincent MilanoCEOBuy200,000$4.00$800,000.00View SEC Filing  
5/27/2014James A GeraghtyDirectorBuy10,000$2.65$26,500.00View SEC Filing  
12/6/2013James A GeraghtyDirectorBuy40,000$2.72$108,800.00View SEC Filing  
9/16/2013James A GeraghtyDirectorBuy60,000$1.90$114,000.00View SEC Filing  
8/19/2013James A GeraghtyDirectorBuy300,000$1.75$525,000.00View SEC Filing  
5/7/2013C Keith HartleyDirectorBuy90,000$0.49$44,100.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Idera Pharmaceuticals (NASDAQ:IDRA)
DateHeadline
News IconAnalyst Research Consensus on Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) CubeSmart (NYSE:CUBE) - Rockville Register (NASDAQ:IDRA)
rockvilleregister.com - February 16 at 4:42 PM
News IconIdera Pharmaceuticals, Inc. (NASDAQ:IDRA) Daily Sentiment Score At 0 - Stock Observer (NASDAQ:IDRA)
www.thestockobserver.com - February 13 at 6:51 PM
News IconFollowing the Numbers for Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) - Benton Bulletin (NASDAQ:IDRA)
bentonbulletin.com - February 10 at 11:37 PM
News IconForward Earnings Estimate of Idera Pharmaceuticals, Inc.(IDRA ... - Highland Mirror (NASDAQ:IDRA)
www.highlandmirror.com - February 10 at 11:37 PM
smarteranalyst.com logoStock Update (NASDAQ:IDRA): Idera Pharmaceuticals Inc Announces Appointment of Jonathan Yingling, Ph.D. as ... - Smarter Analyst (NASDAQ:IDRA)
www.smarteranalyst.com - February 8 at 5:12 AM
News IconIdera Pharmaceuticals Inc (NASDAQ:IDRA): Here Are The Catalysts To Watch - Insider Financial (NASDAQ:IDRA)
www.insiderfinancial.com - February 8 at 5:12 AM
News IconIdera Pharmaceuticals, Inc. (NASDAQ:IDRA) expected to move 3 ... - Post Analyst (NASDAQ:IDRA)
postanalyst.com - February 6 at 10:39 AM
finance.yahoo.com logoIdera Announces Appointment of Jonathan Yingling, Ph.D. as Senior Vice President of Early Development (NASDAQ:IDRA)
finance.yahoo.com - February 6 at 10:38 AM
News IconChecking Indicator Levels for Idera Pharmaceuticals Inc. (IDRA) - Sherwood Daily (NASDAQ:IDRA)
sherwooddaily.com - February 1 at 6:37 PM
seekingalpha.com logoDoubling Down On Idera - Seeking Alpha (NASDAQ:IDRA)
seekingalpha.com - February 1 at 6:37 PM
News IconEarnings Parade Rolls On, What Are Analysts Saying About Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)? - Wall Street Beacon (NASDAQ:IDRA)
wsbeacon.com - February 1 at 4:41 AM
News IconStock Vacillating as Volatility Hits a High Point For Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) - Wall Street Beacon (NASDAQ:IDRA)
wsbeacon.com - February 1 at 4:41 AM
News IconAre Insiders Bumping Up Their Positions in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) - Wall Street Beacon (NASDAQ:IDRA)
wsbeacon.com - February 1 at 4:41 AM
streetinsider.com logoWedbush Assumes Idera Pharmaceuticals (IDRA) at Outperform - StreetInsider.com (NASDAQ:IDRA)
www.streetinsider.com - February 1 at 4:41 AM
News IconChecking the Metrics on Shares of Idera Pharmaceuticals, Inc ... - The Tribune (NASDAQ:IDRA)
lakecitytribune.com - January 28 at 5:58 PM
bizjournals.com logoResearch Reports Coverage on Biotech Stocks -- Idera Pharma, Ocular Therapeutix, Radius Health, and Grifols (NASDAQ:IDRA)
www.bizjournals.com - January 27 at 7:47 PM
News IconStock Spotter: Review on Technical Levels for Idera Pharmaceuticals Inc. (IDRA) - Sherwood Daily (NASDAQ:IDRA)
sherwooddaily.com - January 26 at 7:29 PM
News IconTechnical Toolbox: Investor Focus on Idera Pharmaceuticals Inc. (IDRA) - Sherwood Daily (NASDAQ:IDRA)
sherwooddaily.com - January 24 at 11:38 PM
News IconEarnings in Full Force, Analysts Take Aim at Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) - Wall Street Beacon (NASDAQ:IDRA)
wsbeacon.com - January 24 at 11:38 PM
News IconStock Perspective: Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Company Earnings Watch - Aiken Advocate (NASDAQ:IDRA)
aikenadvocate.com - January 24 at 11:38 PM
News IconValue Composite Score Update on Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) - The Tribune (NASDAQ:IDRA)
lakecitytribune.com - January 23 at 6:07 PM
News IconIdera Pharmaceuticals, Inc. (NASDAQ:IDRA) Quarterly EPS Set At $-0.12 - Stock Observer (NASDAQ:IDRA)
www.thestockobserver.com - January 22 at 3:45 AM
News IconIdera Pharmaceuticals Inc IDRA Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:IDRA)
www.bioportfolio.com - January 21 at 10:43 PM
News IconIdera Pharmaceuticals, Inc. (NASDAQ:IDRA) Bearish Target At $6 - Stock Observer (NASDAQ:IDRA)
www.thestockobserver.com - January 20 at 3:19 PM
News IconShares in View: Idera Pharmaceuticals Inc. (IDRA) - Sherwood Daily (NASDAQ:IDRA)
sherwooddaily.com - January 20 at 3:19 PM
News IconIdera Pharmaceuticals, Inc. (NASDAQ:IDRA) shows monthly volitility of 5.85% - The Newburgh Press (NASDAQ:IDRA)
newburghpress.com - January 12 at 6:19 PM
News IconCan This Stock Pick Up Any Momentum: Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) - Prospect Journal (NASDAQ:IDRA)
prospectjournal.com - January 11 at 11:29 PM
seekingalpha.com logoIdera Pharmaceutical (IDRA) Presents At 35th Annual J.P. Morgan Healthcare Conference (NASDAQ:IDRA)
seekingalpha.com - January 11 at 6:28 PM
News IconUpside Alert: Delving into Shares of Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) - Prospect Journal (NASDAQ:IDRA)
prospectjournal.com - January 9 at 11:33 PM
News IconBargain Hunters Should Take a Look at Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) - Prospect Journal (NASDAQ:IDRA)
prospectjournal.com - January 9 at 11:33 PM
News IconIdera Pharmaceuticals, Inc. (NASDAQ:IDRA) Daily Sentiment Score At 0.56 - Stock Observer (NASDAQ:IDRA)
www.thestockobserver.com - January 9 at 11:33 PM
biz.yahoo.com logoIDERA PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:IDRA)
biz.yahoo.com - January 9 at 6:33 PM
News IconBearish Target Of Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) At $6 ... - Stock Observer (NASDAQ:IDRA)
www.thestockobserver.com - January 6 at 6:28 PM
biz.yahoo.com logoIDERA PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:IDRA)
biz.yahoo.com - January 6 at 6:28 PM
capitalcube.com logoETFs with exposure to Idera Pharmaceuticals, Inc. : January 4, 2017 (NASDAQ:IDRA)
www.capitalcube.com - January 4 at 6:44 PM
finance.yahoo.com logoIdera to Present at the 35th Annual J.P. Morgan Healthcare Conference (NASDAQ:IDRA)
finance.yahoo.com - January 4 at 6:44 PM
News IconDaily Sentiment Score Of Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) At -0.39 - Stock Observer (NASDAQ:IDRA)
www.thestockobserver.com - January 3 at 5:33 PM
News IconMannKind Corporation (NASDAQ:MNKD) , Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) - ODF Report (NASDAQ:IDRA)
odfreport.com - January 1 at 5:43 PM
News IconIs This a Sensible Stock at Current Levels: Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) - Prospect Journal (NASDAQ:IDRA)
prospectjournal.com - December 29 at 10:53 PM
News IconBearish Target Of Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) At $6 - Stock Observer (NASDAQ:IDRA)
www.thestockobserver.com - December 28 at 5:46 PM
capitalcube.com logoETFs with exposure to Idera Pharmaceuticals, Inc. : December 21, 2016 (NASDAQ:IDRA)
www.capitalcube.com - December 21 at 6:43 PM
News IconStock in Focus: Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) - Liberty News (NASDAQ:IDRA)
libertynewsrecord.com - December 20 at 11:09 PM
News IconStock Tracker: Focusing on Shares of Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) - OIB News (NASDAQ:IDRA)
oibnews.com - December 20 at 11:13 AM
News IconStock Vacillating Higher Pre-Bell: Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) - Prospect Journal (NASDAQ:IDRA)
prospectjournal.com - December 20 at 11:13 AM
News IconIdera Pharmaceuticals, Inc. (NASDAQ:IDRA) Daily Sentiment Score At 0.198 - Stock Observer (NASDAQ:IDRA)
www.thestockobserver.com - December 19 at 11:36 AM
News IconInvestor Update: Checking on Shares of Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) - Liberty News (NASDAQ:IDRA)
libertynewsrecord.com - December 19 at 11:36 AM
finance.yahoo.com logoIs the Options Market Predicting a Spike in Idera Pharmaceuticals (IDRA) Stock? (NASDAQ:IDRA)
finance.yahoo.com - December 15 at 6:29 PM
News IconCompany Review: Narrowing in on Shares of Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) - Liberty News (NASDAQ:IDRA)
libertynewsrecord.com - December 15 at 4:39 AM
News IconInvestor Focus on Shares of Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) - OIB News (NASDAQ:IDRA)
oibnews.com - December 13 at 11:21 PM
finance.yahoo.com logoWhy You Shouldn't Bet Against Idera (IDRA) Stock (NASDAQ:IDRA)
finance.yahoo.com - December 13 at 6:19 PM

Social

What is Idera Pharmaceuticals' stock symbol?

Idera Pharmaceuticals trades on the NASDAQ under the ticker symbol "IDRA."

Where is Idera Pharmaceuticals' stock going? Where will Idera Pharmaceuticals' stock price be in 2017?

3 brokerages have issued 12 month price objectives for Idera Pharmaceuticals' stock. Their forecasts range from $2.10 to $6.00. On average, they expect Idera Pharmaceuticals' share price to reach $4.05 in the next twelve months.

When will Idera Pharmaceuticals announce their earnings?

Idera Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March, 8th 2017.

What are analysts saying about Idera Pharmaceuticals stock?

Here are some recent quotes from research analysts about Idera Pharmaceuticals stock:

  • Wedbush analysts commented, "IDRA is focused on pursuing an aggressive development strategy for IMO-2125 in light of durable responses in its ongoing Ph 1 study in PD-1 refractory melanoma. We believe the recently presented translational data demonstrating evidence of mechanism support a wider opportunity in improving the response to checkpoint agents in additional immunogenic tumors, as potentially broadening their utility to less immunogenic tumors." (1/31/2017)
  • According to Zacks Investment Research, "Idera Pharmaceuticals, Inc. is a drug discovery and development company that is developing drug candidates to treat cancer and infectious, respiratory, and autoimmune diseases, and for use in combination with therapeutic and prophylactic vaccines. Idera's proprietary drug candidates are designed to modulate Toll-like Receptors, the body's first line of immune defense. Idera's pioneering DNA chemistry expertise enables it to identify drug candidates for internal development and creates opportunities for multiple collaborative alliances. " (1/30/2017)

Who owns Idera Pharmaceuticals stock?

Idera Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Broadfin Capital LLC (3.00%), FMR LLC (1.70%), State Street Corp (1.05%), Alyeska Investment Group L.P. (0.74%) and Palo Alto Investors LLC (0.42%). Company insiders that own Idera Pharmaceuticals stock include James A Geraghty, Julian Baker, Mark J Casey, Maxine Gowen and Vincent Milano.

Who sold Idera Pharmaceuticals stock? Who is selling Idera Pharmaceuticals stock?

Idera Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Palo Alto Investors LLC.

Who bought Idera Pharmaceuticals stock? Who is buying Idera Pharmaceuticals stock?

Idera Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Broadfin Capital LLC, Alyeska Investment Group L.P. and State Street Corp. Company insiders that have bought Idera Pharmaceuticals stock in the last two years include James A Geraghty, Julian Baker, Mark J Casey, Maxine Gowen and Vincent Milano.

How do I buy Idera Pharmaceuticals stock?

Shares of Idera Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Idera Pharmaceuticals stock cost?

One share of Idera Pharmaceuticals stock can currently be purchased for approximately $1.74.

Idera Pharmaceuticals (NASDAQ:IDRA) Chart for Sunday, February, 19, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Idera Pharmaceuticals (NASDAQ:IDRA)

Earnings History Chart

Earnings by Quarter for Idera Pharmaceuticals (NASDAQ:IDRA)

Dividend History Chart

Dividend Payments by Quarter for Idera Pharmaceuticals (NASDAQ:IDRA)

Last Updated on 2/19/2017 by MarketBeat.com Staff